PD-1 antibody after surgery for bile duct cancer
Part of Cancer clinical trials.
This Phase 2 trial studies whether adding a PD-1 antibody plus gemcitabine/oxaliplatin (GEMOX) after surgery can lower the chance of the cancer coming back in perihilar cholangiocarcinoma. It’s for people who have had surgery with no tumor left at the cut edges, but lymph nodes showed cancer under the microscope.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign informed consent and are age 18–75
- You are able to do daily activities fairly normally (ECOG 0–1)
- Your liver function tests and overall blood counts must be in safe ranges (including Child-Pugh A)
- Your hepatitis B/C virus levels must be controlled, and you must not have uncontrolled infections
- No cancer medicines for at least 6 months before joining
- You have at least one visible tumor spot on scans to measure (measurable lesion)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy (gemcitabine and cisplatin) combined with immunotherapy (pembrolizumab) before and after surgery can improve outcomes compared to having surgery right away. It is for people with bile duct cancer that can be removed or is borderline removable.
This trial tests a combination of chemotherapy, immunotherapy (adebrelimab), and a targeted therapy (apatinib) before and after surgery for bile duct cancer that can be removed and has a high risk of coming back. It aims to see if this approach can lower the chance of recurrence.
This trial tests a combination of radiation therapy (PULSAR), immunotherapy, and chemotherapy for advanced bile duct cancer. It aims to see if this approach can shrink tumors and improve survival.
This trial uses a test called MiniPDX, which grows a tiny sample of your tumor in mice to see which drugs work best. After your surgery, you'll receive chemotherapy chosen specifically for your cancer to help prevent it from coming back.
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
This trial tests a specific chemotherapy after surgery for people with stage II or III bile duct, gallbladder, or ampullary cancer. It may help reduce the chance of cancer coming back.
Hear when a new Perihilar Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.